Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells
- 1 March 2014
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 68 (2) , 179-183
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Role of microRNA in anticancer drug resistanceInternational Journal of Cancer, 2009
- Nuclear cyclin D1: An oncogenic driver in human cancerJournal of Cellular Physiology, 2009
- Reversal of P‐glycoprotein‐mediated multi‐drug resistance by the E3 ubiquitin ligase Cbl‐b in human gastric adenocarcinoma cellsThe Journal of Pathology, 2009
- miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cellsInternational Journal of Cancer, 2008
- Recent advances in P-gp-mediated MDR reversal mechanismsMethods and Findings in Experimental and Clinical Pharmacology, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Mechanisms of Disease: PI3K/AKT Signaling in Gastrointestinal CancersZeitschrift für Gastroenterologie, 2005
- Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancerInternational Journal of Cancer, 2005
- Tamoxifen Induction of Apoptosis in Estrogen Receptor-Negative Cancers: New Tricks for an Old Dog?JNCI: Journal of the National Cancer Institute, 1996
- Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4Genes & Development, 1993